



# NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab), Corporate Identification Number: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email : sunderlal@necLife.com, Website : www.necLife.com

Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2014 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	9 Month ended	9 Month ended	Year ended
		31-12-14	30-09-14	31-12-13	31-12-14	31-12-13	31-03-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	<b>Income from Operations</b>						
	(a) Gross Sales	47147.37	42113.15	40700.32	129474.06	122600.30	170818.37
	Less : Excise Duty	2735.69	2739.58	1596.41	7531.02	4863.47	7041.45
	Net Sales	44411.68	39373.57	39103.91	121943.04	117736.83	163776.92
	(b) Other Operating Income	32.29	15.14	6.80	61.48	20.22	54.29
	<b>Total Income from Operations (net)</b>	<b>44443.97</b>	<b>39388.71</b>	<b>39110.71</b>	<b>122004.52</b>	<b>117757.05</b>	<b>163831.21</b>
2.	<b>Expenses</b>						
	(a) Cost of Materials consumed	29783.10	24794.12	24867.91	79893.36	80541.43	117267.14
	(b) Purchase of Stock in Trade	1528.22	725.92	577.99	3678.31	3835.16	3982.32
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	178.79	1043.70	568.14	1080.93	(3190.55)	(5781.06)
	(d) Employee benefits expense	1501.69	1463.37	1303.99	4352.2	3959.18	5132.87
	(e) Depreciation and amortisation expense	1907.31	1887.72	2104.07	5718.29	6342.51	8418.57
	(f) Other expenses	4154.93	4129.75	3841.16	11896.98	11209.28	14353.11
	<b>Total Expenses</b>	<b>39054.04</b>	<b>34044.58</b>	<b>33263.26</b>	<b>106620.07</b>	<b>102697.01</b>	<b>143372.95</b>
3.	<b>Profit from Operations before Other Income, finance costs and exceptional Items (1-2)</b>	<b>5389.93</b>	<b>5344.13</b>	<b>5847.45</b>	<b>15384.45</b>	<b>15060.04</b>	<b>20458.26</b>
4.	Other Income	221.72	266.31	244.40	718.26	1072.30	1162.75
5.	<b>Profit before finance costs and exceptional Items (3+4)</b>	<b>5611.65</b>	<b>5610.44</b>	<b>6091.85</b>	<b>16102.71</b>	<b>16132.34</b>	<b>21621.01</b>
6.	Finance costs	3482.54	3548.48	3983.04	9871.13	10501.61	13798.74
7.	<b>Profit after finance costs but before exceptional Items (5-6)</b>	<b>2129.11</b>	<b>2061.96</b>	<b>2108.81</b>	<b>6231.58</b>	<b>5630.73</b>	<b>7822.27</b>
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	<b>Profit from ordinary activities before tax (7+8)</b>	<b>2129.11</b>	<b>2061.96</b>	<b>2108.81</b>	<b>6231.58</b>	<b>5630.73</b>	<b>7822.27</b>
10.	<b>Tax Expense</b>	<b>440.58</b>	<b>420.17</b>	<b>395.75</b>	<b>1276.22</b>	<b>1292.40</b>	<b>1614.28</b>
11.	<b>Net Profit from ordinary activities after tax (9-10)</b>	<b>1688.53</b>	<b>1641.79</b>	<b>1713.06</b>	<b>4955.36</b>	<b>4338.33</b>	<b>6207.99</b>
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	<b>Net Profit for the period (11-12)</b>	<b>1688.53</b>	<b>1641.79</b>	<b>1713.06</b>	<b>4955.36</b>	<b>4338.33</b>	<b>6207.99</b>
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	90463.57
16.i	<b>Earnings per Share (EPS) (before extraordinary items)</b>						
	a) Basic	0.75	0.73	0.76	2.21	1.93	2.77
	b) Diluted	0.75	0.73	0.76	2.21	1.93	2.77
16.ii	<b>Earnings per Share (EPS) (after extraordinary items)</b>						
	a) Basic	0.75	0.73	0.76	2.21	1.93	2.77
	b) Diluted	0.75	0.73	0.76	2.21	1.93	2.77

## Part II Select Information for the Quarter and Nine month ended 31.12.2014

Part II Select Information for the Quarter and Nine month ended 31.12.2014							
A	Particulars of shareholding						
1.	<b>Public Shareholding</b>						
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65
2.	<b>Promoters and Promoter Group Shareholding</b>						
	<b>a) Pledged/Encumbered</b>						
	- Number of Shares	55,555,600	55,555,600	-	55,555,600	-	-
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	55.85	55.85	-	55.85	-	-
	- Percentage of Shares ( as a % of the total share capital of the company)	24.77	24.77	-	24.77	-	-
	<b>b) Non-encumbered</b>						
	- Number of Shares	43,912,400	43,912,400	99,468,000	43,912,400	99,468,000	99,468,000
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	44.15	44.15	100.00	44.15	100.00	100.00
	- Percentage of Shares ( as a % of the total share capital of the company)	19.58	19.58	44.35	19.58	44.35	44.35
B	<b>Investor Complaints</b>	<b>3 Months ended 31.12.2014</b>					
	Pending at the beginning of Quarter	-					
	Received During the Quarter	13					
	Disposed Off During the Quarter	13					
	Pending at the end of Quarter	-					

### Notes:

- 1 The above financial results were reviewed by Audit Committee on 12.02.15 and approved by the Board in its meeting held on even date i.e. 13.02.15 and further limited reviewed by the Statutory Auditors of the Company.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The above financial results are on stand alone basis.

**By Order of the Board of Directors  
of Nectar Lifesciences Limited  
Sd/-**

(Dinesh Dua)

Dated: 13.02.2015

Place: Chandigarh

Chief Executive Officer & Director